Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 425809 With and Without Bosentan in Healthy Males
NCT05723874Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve at Steady State Over a Uniform Dosing Interval and Maximum Measured Concentration at Steady State Over a Uniform Dosing Interval. Started Mar 2023; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05723874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723874.